NASHVILLE, Tennessee & COLUMBUS, Ohio – (BUSINESS WIRE) – Raoul S. Concepcion, MD, FACS, joined US Urology Partners as Chief Science Officer. As one of the nation’s largest independent providers of specialty urology and related services, US Urology Partners provides general urology, surgical procedures, advanced cancer treatment for prostate, bladder and kidney cancer, and other ancillary services.
Dr. Concepcion will lead the scientific operations of US Urology Partners’ rapidly growing clinical network, which now includes 24 locations through partners Central Ohio Urology Group and Associated Medical Professionals of NY. Dr. Concepcion has decades of experience as a pioneer and clinician at the forefront of the urology industry, including as a founding board member and former president of LUGPA, the leading non-profit association and advocate of independent urological practices.
Mark Cherney, Chief Executive Officer of US Urology Partners, said, “We are pleased that Dr. Raoul Concepcion joined US Urology Partners as Chief Science Officer. His many years of experience in urological clinical research programs and analytics will support US Urology Partners and their partner practices in providing optimal patient care. Dr. Concepcion will be particularly helpful in advancing our precision medicine program, including genomics, genetic testing and counseling. ”
Because urological practices are looking for an alternative to buying a hospital that allows them to focus on medical practice rather than business affairs, they turn to US Urology Partners. Founded in 2018, US Urology Partners supports urological practices through an experienced team of healthcare executives and resources and is funded by NMS Capital.
Raoul S. Concepcion, Dr. As Chief Science Officer, I will work with key physicians from member practices to establish a precision medicine cancer management model for affiliated groups that incorporates evidence-based treatment guidelines, establishes a clinical genome medicine service, and builds a centralized clinical trial initiative. The aim is to improve patient care and advance science, which in turn offers the partner practices added value. ”
He added, “The establishment of a precision medicine platform will enable the team at US Urology Partners and its affiliated urology groups to provide the right treatment to the right patient. In the past 10 years, the incorporation of advanced cancer therapies into urological practice has become established. This now also requires an understanding of genetic and genomic tests in order to optimize the care of these patients, similar to the standard of care for breast and colon tumors. Hence, it represents for the busy clinician, supported by US Urology Partners and their Medical Advisory Team, of which I am proud to be a part, assists, to keep up to date with the rapidly evolving data and to keep up to date stay.”
Dr. Concepcion is from central Ohio and was a clinical assistant professor in the Department of Urology at the Vanderbilt School of Medicine. From 1984 to 1989 he was an assistant doctor for general surgery and urology and from 1989 to 1990 chief doctor for urology. He was also a research fellow at Light Laboratories in Vanderbilt. More recently, he has completed the City of Hope Intensive Course in Cancer Risk Assessment for Hereditary Cancer and Genomic Testing. He has been with the practice since 1990, with his primary clinical interest in urological oncology, specializing in advanced prostate and bladder cancer and lower urinary tract reconstruction, as well as the role of genomics and genetic testing in GU tumors. He is certified and a member of the American Urological Association (AUA) as well as the Southeastern Section of the AUA, the Society of Urologic Oncology, the American College of Surgeons and the Nashville Surgical Society.
From a scientific point of view, Dr. Concepcion has been actively involved in basic and clinical research since joining Vanderbilt. Dr. Concepcion has been either the Principal Investigator (PI) or Co-PI in many clinical trials since the 1990s. The focus lately has been on advanced prostate cancer and the development of biomarkers. He co-founded CUSP, a urology-specific clinical trial management company that specializes in location and patient tracking for the pharmaceutical and bio-laboratory industries. From an industry perspective, Dr. Concepcion has worked as a consultant, consultant or speaker for many companies dealing with the diagnosis and treatment of prostate cancer. He is developing a comprehensive precision medicine prostate cancer program for US urology partners and affiliated groups, focusing on genome testing, pathway development, data aggregation and clinical trials.
Via US urology partners
US Urology Partners is one of the largest independent providers of urology and related specialty services in the country, including general urology, surgical procedures, advanced cancer care, and other ancillary services. Through the Central Ohio Urology Group and Associated Medical Professionals of NY, US Urology Partners’ clinical network now consists of 24 offices, including a state-of-the-art, urology-specific outpatient surgery center, one of the first in the country to offer robotic surgery. US Urology Partners was founded to support urological practices through an experienced team of healthcare executives and resources while serving as the platform on which NMS Capital intends to develop a leading urological services provider through an acquisition strategy. US Urology Partners has corporate offices in Nolensville, Tennessee and Gahanna, Ohio, just outside of Nashville and Columbus. For more information on US urology partners, please visit the company’s website at www.us-uro.com.
source https://dailyhealthynews.ca/u-s-urology-partners-names-healthcare-visionary-raoul-s-concepcion-m-d-as-chief-science-officer/
No comments:
Post a Comment